Search

Displaying results 1091 - 1100 of 8195 in total
  1. Drug

    Hydroxyzine

    go.drugbank.com/drugs/DB00557
    ApprovedInvestigational

    [L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect.

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Nu-hydroxyzine
  2. Drug

    Gelatin

    go.drugbank.com/drugs/DB11242
    ApprovedInvestigationalVet approvedWithdrawn

    An increasing number of novel applications have been found for collagen and gelatin.[A32426] Gelatin is generally recognized as safe (GRAS) by the FDA to be a non-hazardous food or food ingredient.

  3. Drug

    Vevorisertib

    go.drugbank.com/drugs/DB21481
    Investigational

    Vevorisertib has a monoisotopic molecular weight of 586.32 Da. … Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations

  4. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole, 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole
  5. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: Nu-bicalutamide, Van-bicalutamide
  6. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. … [A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.

    Mixtures: XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA, XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADACategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. … Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades.

  8. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [L44667] Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. … Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia

    Products: ONCASPAR® 750 U/ML POLVO PARA SOLUCIÓN INYECTABLE, ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML
  9. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [L10403] and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. … Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates